Several preclinical studies using transgenic models with an altered calpain/calpastatin system and pharmacological inhibitors support the contribution of calpains to the development of cardiac hypertrophy and its progression to adverse remodeling and cardiac dysfunction. The gene discussed is CAST; the disease is cardiac hypertrophy.